{"id":"W2168372454","doi":"10.1200/jco.2014.56.9590","title":"Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Hazard ratio; Breast cancer; Docetaxel; Clinical endpoint; Pertuzumab; Cancer; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123461,0.0006937423,0.001390591,0.0004360103,0.0002544093,0.0007501699,0.0006688827,0.0006852981,0.003538113],"category_scores_gemma":[0.002125938,0.0002218805,0.001653106,0.0005929329,0.0003390659,0.000399261,0.000293019,0.001424643,0.0004292952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052125,"about_ca_system_score_gemma":0.001122738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003563232,"about_ca_topic_score_gemma":0.01222069,"domain_scores_codex":[0.9990616,0.0006679098,0.00004122339,0.00006286644,0.00008606946,0.00008029996],"domain_scores_gemma":[0.9990245,0.0003349871,0.0002235293,0.00008214161,0.0001069619,0.0002279336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5007622,0.006488906,0.02876819,0.004942805,0.009550965,0.0004625252,0.0002576141,0.007793945,0.0133325,0.0009318235,0.0323006,0.3944079],"study_design_scores_gemma":[0.5814956,0.1816966,0.1515425,0.001535949,0.01684598,0.001014878,0.0001308041,0.003043957,0.006476734,0.0006910427,0.05542626,0.00009964837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8545858,0.1093532,0.001076869,0.003666921,0.0004771285,0.003457853,0.007555474,0.0001447791,0.01968206],"genre_scores_gemma":[0.9506556,0.01824564,0.002167054,0.003352004,0.0006733998,0.002323132,0.01314145,0.00007741765,0.009364241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003563232,"threshold_uncertainty_score":0.01183611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3663924786049742,"score_gpt":0.5653644802031109,"score_spread":0.1989720015981367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}